Literature DB >> 17481719

Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2.

Mino Yoshioka1, Nobuyuki Fukuishi, Sayuri Iriguchi, Kanae Ohsaki, Hiroyuki Yamanobe, Asumi Inukai, Daisuke Kurihara, Naoki Imajo, Yumiko Yasui, Nobuaki Matsui, Tadayuki Tsujita, Akihiro Ishii, Tsukasa Seya, Makoto Takahama, Masaaki Akagi.   

Abstract

BACKGROUND: FcepsilonRI on the surface of mast cells (MCs) plays a central role in allergic responses. Recent evidence shows that exposure to microbial components corresponds with a significant reduction in the risk for allergic diseases. Although many reports suggest that this is due to changes in T-cell functions, how MC functions are altered by bacterial infection remains unknown.
OBJECTIVE: We sought to elucidate the effect of bacterial infection on MC function and expression of Fc receptors, such as FcepsilonRI.
METHODS: Isolated human pulmonary MCs and a human MC line (LAD2) were stimulated with bacterial components, and the function and surface expression of Fc receptors were measured.
RESULTS: Lipoteichoic acid (LTA) and peptidoglycan, but not LPS, flagellin, or 3CpG-oligodeoxynucleotide, reduced the expression of FcepsilonRI on LAD2 cells. An antibody to Toll-like receptor (TLR) 2 partially blocked the effect of LTA but not peptidoglycan. Both LTA and peptidoglycan reduced MC degranulation caused by an antigen-specific IgE. Furthermore, exposure of pulmonary MCs to LTA reduced both FcepsilonRI expression and IgE-induced degranulation. None of the bacterial components affected the expression of other Fc receptors, such as Fcgamma receptors or Fcalpha receptor I.
CONCLUSIONS: Our results indicate that LTA reduces the surface expression of FcepsilonRI through TLR2 and suggests that TLR2 ligands could be used as a novel therapy for controlling allergic disorders. CLINICAL IMPLICATIONS: By knowing how bacterial components modulate MC function, we can expand our possibilities for therapeutic interventions of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17481719     DOI: 10.1016/j.jaci.2007.03.027

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  30 in total

Review 1.  Host-bacterial symbiosis in health and disease.

Authors:  Janet Chow; S Melanie Lee; Yue Shen; Arya Khosravi; Sarkis K Mazmanian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Lipoteichoic acid improves the capability of mast cells in the host defense system against bacteria.

Authors:  Naoki Imajo; Daisuke Kurihara; Nobuyuki Fukuishi; Asumi Inukai; Shinobu Matsushita; Shingo Noda; Mako Toyoda; Mino Yoshioka; Hayato Teruya; Yumiko Nishii; Nobuaki Matsui; Masaaki Akagi
Journal:  Inflamm Res       Date:  2009-05-26       Impact factor: 4.575

Review 3.  Mast Cell-Mediated Orchestration of the Immune Responses in Human Allergic Asthma: Current Insights.

Authors:  Daniel Elieh Ali Komi; Leif Bjermer
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

Review 4.  The impact of bacterial infection on mast cell degranulation.

Authors:  Jordan Wesolowski; Fabienne Paumet
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

5.  Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells.

Authors:  Bodi Zhang; Zuyi Weng; Nikolaos Sismanopoulos; Sharhzad Asadi; Anastasia Therianou; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Orian Shirihai; Theoharis C Theoharides
Journal:  Int Arch Allergy Immunol       Date:  2012-04-27       Impact factor: 2.749

6.  Escherichia coli exposure inhibits exocytic SNARE-mediated membrane fusion in mast cells.

Authors:  Jordan Wesolowski; Fabienne Paumet
Journal:  Traffic       Date:  2014-03-07       Impact factor: 6.215

Review 7.  Mast cells: multitalented facilitators of protection against bacterial pathogens.

Authors:  Nikita H Trivedi; M Neal Guentzel; Annette R Rodriguez; Jieh-Juen Yu; Thomas G Forsthuber; Bernard P Arulanandam
Journal:  Expert Rev Clin Immunol       Date:  2013-02       Impact factor: 4.473

8.  Lipopolysaccharide suppresses IgE-mast cell-mediated reactions.

Authors:  N Wang; M McKell; A Dang; A Yamani; L Waggoner; S Vanoni; T Noah; D Wu; A Kordowski; J Köhl; K Hoebe; S Divanovic; S P Hogan
Journal:  Clin Exp Allergy       Date:  2017-10-10       Impact factor: 5.018

9.  Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury.

Authors:  Yuping Lai; Anna Di Nardo; Teruaki Nakatsuji; Anke Leichtle; Yan Yang; Anna L Cogen; Zi-Rong Wu; Lora V Hooper; Richard R Schmidt; Sonja von Aulock; Katherine A Radek; Chun-Ming Huang; Allen F Ryan; Richard L Gallo
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

10.  FcεR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment.

Authors:  Rohit Saluja; Ingrid Delin; Gunnar P Nilsson; Mikael Adner
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.